Nanomedicines as Cancer Therapeutics: Current Status
Sohail Akhter(Teva Pharmaceuticals (United Kingdom)), Robbert J. Kok(Utrecht University), Ziyaur Rahman, Mohammad Zaki Ahmad(Najran University), Iqbal Ahmad(Jamia Hamdard), Farhan Jalees Ahmad(Jamia Hamdard), Anjali Singh(Jamia Hamdard), Gert Storm(Yong In University), Farshad Ramazani(Utrecht University)
Cited by 145
Related Papers
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
Sheddable Coatings for Long-Circulating Nanoparticles
|Pharmaceutical Research|2007|549
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Diverse origins of the myofibroblast—implications for kidney fibrosis
|Nature Reviews Nephrology|2015|305